Bayer AG Stock (DE000BAY0017): Berenberg lifts its price target while legal risk stays in view

Bayer shares are in focus after Berenberg raised its price target to 40.50 euros from 40.00 euros and kept a Hold rating. The stock traded around 35.91 euros on XETRA on Friday.

Responsible: ad hoc news Markets & Valuation Desk. Reviewed prior to publication on June 12, 2026 at 8:19 PM ET. Details in the imprint.

Bayer shares were in focus on Friday after Berenberg raised its price target to 40.50 euros from 40.00 euros and kept its Hold rating on the stock. Finanzen.net reported that the shares traded at 35.91 euros on XETRA at the time of publication, while 4investors.de also cited the same move in its coverage of the analyst note.

Why the latest analyst note matters

The updated target gives the market another reference point for Bayer's valuation, but it does not change the broader debate around the company's legal overhang. According to 4investors.de, UBS remains more constructive with a 52-euro target and a Buy rating, showing that analyst views on the stock still span a wide range.

That spread matters because Bayer's share price is still being judged against both operating performance and litigation risk. 4investors.de said Berenberg sees a 60% chance of a favorable U.S. Supreme Court outcome in the Durnell case, yet the analysts still described the possible paths in the Glyphosate dispute as highly complex.

The stock's modest intraday move also suggests the note was interpreted as incremental rather than transformative. Finanzen.ch reported Bayer was up 0.6% at 35.99 euros in afternoon trading, after earlier moving between 35.68 euros and 36.21 euros on XETRA.

Against that backdrop, Bayer remains a stock where valuation work is tightly linked to court developments, margin expectations, and peer comparisons among large-cap German healthcare and agriculture names. The latest analyst updates add to that picture, but they do not remove the legal uncertainty that continues to shape sentiment.

Key facts on Bayer AG stock

• Name: Bayer AG
• Industry: Pharmaceuticals and crop science
• Headquarters: Leverkusen, Germany
• Core markets: Europe, the United States, and other global markets
• Revenue drivers: Prescription medicines, consumer health products, seeds, and crop protection
• Listing: XETRA: BAYN; ADS no verified U.S. listing in the provided sources
• Trading currency: Euro

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.